Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast
Publication Date: October 1, 2018
Last Updated: March 14, 2022
Recommendations
Indications for cryoablation or percutaneous excision of a fibroadenoma:
a. The lesion must be easily visualized on ultrasound.
b. The diagnosis of fibroadenoma must be confirmed histologically on core biopsy prior to treatment.
c. The diagnosis of fibroadenoma must be concordant with the imaging findings, patient history, and physical exam.
d. Lesions should be less than 4 cm in largest diameter.
b. The diagnosis of fibroadenoma must be confirmed histologically on core biopsy prior to treatment.
c. The diagnosis of fibroadenoma must be concordant with the imaging findings, patient history, and physical exam.
d. Lesions should be less than 4 cm in largest diameter.
6731
Indications for focused ultrasound ablation for the treatment of fibroadenoma:
Focused ultrasound ablation for the treatment of fibroadenoma is currently under investigation in the United States, and is not approved by the FDA for this indication. This technique is considered investigational and should not be performed outside the realm of a clinical trial. There is an ongoing FDA-approved clinical trial for “echotherapy” in the treatment of fibroadenomas.
6731
Indications for percutaneous and/or transcutaneous ablative treatments of malignant tumors of the breast:
Cryoablation is currently approved for treatment of benign and malignant soft tissue tumors by the FDA. Currently, there are no specific technologies that have FDA approval for breast tumors. Participation in registries and clinical trials evaluating the use of these technologies with and without surgical excision of a breast malignancy is advised as early data emerges on their efficacy.
6731
Recommendation Grading
Overview
Title
Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast
Authoring Organization
American Society of Breast Surgeons
Publication Month/Year
October 1, 2018
Last Updated Month/Year
January 23, 2024
Document Type
Consensus
External Publication Status
Published
Country of Publication
US
Document Objectives
To outline current data on transcutaneous and percutaneous ablation methods for treatment of benign and malignant tumors of the breast.
Inclusion Criteria
Female, Male, Adult, Older adult
Health Care Settings
Operating and recovery room, Outpatient, Radiology services
Intended Users
Radiology technologist, clinical researcher, nurse, nurse practitioner, physician, physician assistant
Scope
Management, Treatment
Diseases/Conditions (MeSH)
D001943 - Breast Neoplasms, D018226 - Fibroadenoma
Keywords
fibroadenomas, Tumors of the Breast, Percutaneous Ablation, Transcutaneous Ablation